Back to Peptides

FOXO4-DRI

Anti-Aging & Skin Health

FOXO4-DRI is a synthetic senolytic peptide that promotes apoptosis of senescent cells by disrupting the FOXO4-p53 interaction. It has demonstrated anti-aging potential by improving tissue function, reducing inflammation, and restoring youthful cellular profiles in preclinical aging models.

Reconstitute
3 mL BAC + 10mg vial
33 mcg/unit
Daily Range
1–5 mg Subcutaneous (SQ)
Once daily for 3–5 days per cycle
Standard Dose
2 mg
Cycle
4–8 weeks
then reassess
FOXO4-DRIsenolytic peptideanti-agingp53 modulatorsenescent cell clearance

Dosing & Reconstitution Guide

In murine studies, FOXO4-DRI was administered at 5–10 mg/kg via intraperitoneal injection. Not tested in human trials.

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Week 1 (Days 1–7)300 mcg9 units (0.09 mL)
Week 2 (Days 8–14)OffNo injection
Week 3 (Days 15–21)400 mcg12 units (0.12 mL)
Week 4 (Days 22–28)OffNo injection

Protocol Summary

Subcutaneous (SQ): Once daily for 3–5 days per cycle · Dose range 1–5 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Typical protocol: 2–5 mg SubQ daily for 3–5 days. Repeat cycle every 3–6 months depending on aging status and tissue health markers.

🧪 Quick Start

Vial Size
10 mg
BAC Water
3 mL
Concentration
3.33 mcg/unit
Starting Dose
300 mcg (9 units (0.09 mL))
Maintenance Dose
Off (No injection)

Potential Benefits & Use Cases

FOXO4-DRI is a research-only compound and not approved for human use in any country.
Supports selective clearance of senescent cells while sparing healthy, proliferating cells (preclinical)
Improves physical fitness, fur density, and organ function in aged mice (preclinical)
Restores testosterone levels by clearing senescent Leydig cells in aged mice (preclinical)
Reduces fibrotic tissue damage in pulmonary fibrosis models (preclinical)
Increases apoptosis of senescent renal tubular cells, supporting kidney function in aged mice (preclinical)
Shows promise in cartilage regeneration via human chondrocyte expansion models (in vitro)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Disrupts interaction between FOXO4 and p53, a protective axis in senescent cells
→Releases p53 from nuclear entrapment, leading to apoptosis in damaged senescent cells
→Promotes selective clearance of dysfunctional cells to restore tissue homeostasis
→Lowers SASP (senescence-associated secretory phenotype) inflammation markers

Lifestyle & Optimization

timing

Cycled protocols — active weeks followed by off-weeks.

diet

Balanced nutrient-dense diet.

exercise

Regular physical activity.

sleep

Quality sleep. Adequate rest during off-weeks for cell clearance and tissue remodeling.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Cell — Baar MP et al. (2017) Targeted apoptosis of senescent cells restores tissue homeostasisReference
Nature Medicine — van Deursen JM (2014) The role of senescent cells in ageingReference
Aging Cell — Zhu Y et al. (2015) The Achilles' heel of senescent cells: from transcriptome to senolytic drugsReference
Nature Reviews Drug Discovery — Kirkland JL, Tchkonia T (2020) Senolytic drugsReference
PMC — Cellular senescence and agingReference

Side Effects & Safety

Contraindications & Warnings

• Theoretical oncogenic risk — p53 pathway interference (theoretical)
• Potential immune overload from rapid senescent cell clearance (theoretical)

🧮 Dose Calculator

Concentration
33.3
mcg/unit
Draw Volume
15
units (0.150 mL)
For a 500 mcg dose, draw 15 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Effective for systemic senescent cell targeting with SubQ injection
Oral Administration
Not bioavailable orally due to proteolysis
Half-Life
Not precisely defined; prolonged activity observed in preclinical studies
Degradation
Metabolized by proteases; D-retro-inverso modifications enhance resistance
Tissue Specificity
Targets senescent cells in aging tissues including muscle, fat, skin, and vasculature
⚗️

Peptide Details

Molecular Weight
1385.6
Formula
C63H100N18O19S2
Sequence
DRI-modified FOXO4 sequence (D-retro-inverso analog)
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (36–46 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (36–46 °F); use within 28 days with bacteriostatic water